Expert Review of Pharmacoeconomics & Outcomes Research, Volume 21, Issue 3 (2021)

Browse this journal
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Expert Review of Pharmacoeconomics & Outcomes Research, Volume 21, Issue 3 (2021)

See all volumes and issues
Vol 24, 2024 Vol 23, 2023 Vol 22, 2022 Volume 21, 2021 Vol 20, 2020 Vol 19, 2019 Vol 18, 2018 Vol 17, 2017 Vol 16, 2016 Vol 15, 2015 Vol 14, 2014 Vol 13, 2013 Vol 12, 2012 Vol 11, 2011 Vol 10, 2010 Vol 9, 2009 Vol 8, 2008 Vol 7, 2007 Vol 6, 2006 Vol 5, 2005 Vol 4, 2004 Vol 3, 2003 Vol 2, 2002 Vol 1, 2001
Download citations Download PDFs Download issue

Pharmacoeconomics in Oncology: Direct and Indirect Costs

Editorial

Editorial
Can we achieve affordable cancer medicine prices? Developing a pathway for change
Sabine Vogler
Pages: 321-325
Published online: 12 Mar 2021
First Page PreviewforCan we achieve affordable cancer medicine prices? Developing a pathway for change | Full Text | References | PDF (201.7 KB) | EPUB
  • 2243 Views
  • 8 CrossRef citations
  • 0Altmetric
Free Access
Editorial
How do biosimilars sustain value, affordability, and access to oncology care?
Steven Simoens
Pages: 327-329
Published online: 08 Sep 2020
First Page PreviewforHow do biosimilars sustain value, affordability, and access to oncology care? | Full Text | References | PDF (155 KB) | EPUB
  • 153 Views
  • 8 CrossRef citations
  • 0Altmetric
Editorial
Not cost-effective at zero price: valuing and paying for combination therapies in cancer
Nicholas R Latimer, Adrian Towse & Chris Henshall
Pages: 331-333
Published online: 09 Feb 2021
First Page PreviewforNot cost-effective at zero price: valuing and paying for combination therapies in cancer | Full Text | References | PDF (192.6 KB) | EPUB
  • 4157 Views
  • 7 CrossRef citations
  • 0Altmetric
Free Access

Perspective

Article
Assessing the pricing and benefits of oncology products: an update
Panagiotis Petrou
Pages: 335-342
Published online: 25 May 2021
AbstractforAssessing the pricing and benefits of oncology products: an update | Full Text | References | PDF (251.8 KB) | EPUB
  • 167 Views
  • 3 CrossRef citations
  • 0Altmetric

Review

Early technology assessment of using whole genome sequencing in personalized oncology
Martijn Simons, Michiel Van De Ven, Veerle Coupé, Manuela Joore, Maarten IJzerman, Erik Koffijberg, Geert Frederix, Carin Uyl - De Groot, Edwin Cuppen, Wim Van Harten & Valesca Retèl
Pages: 343-351
Published online: 01 Jun 2021
AbstractforEarly technology assessment of using whole genome sequencing in personalized oncology | Full Text | References | PDF (1.2 MB) | EPUB
  • 3877 Views
  • 2 CrossRef citations
  • 0Altmetric
Open Access
Cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases: an overview of systematic reviews
Vakaramoko Diaby, Reem D. Almutairi, Aram Babcock, Richard K. Moussa & Askal Ali
Pages: 353-364
Published online: 01 Dec 2020
AbstractforCost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases: an overview of systematic reviews | Full Text | References | PDF (2.3 MB) | EPUB | Supplemental
  • 346 Views
  • 5 CrossRef citations
  • 0Altmetric
Economic analyses of immune-checkpoint inhibitors to treat lung cancer
Alain Vergnenegre & Christos Chouaid
Pages: 365-371
Published online: 24 Dec 2020
AbstractforEconomic analyses of immune-checkpoint inhibitors to treat lung cancer | Full Text | References | PDF (568.3 KB) | EPUB
  • 303 Views
  • 0 CrossRef citations
  • 0Altmetric

Systematic Review

Will the Markov model and partitioned survival model lead to different results? A review of recent economic evidence of cancer treatments
Mingjun Rui, Yingcheng Wang, Zhengyang Fei, Xueke Zhang, Ye Shang & Hongchao Li
Pages: 373-380
Published online: 11 Mar 2021
AbstractforWill the Markov model and partitioned survival model lead to different results? A review of recent economic evidence of cancer treatments | Full Text | References | PDF (465.8 KB) | EPUB | Supplemental
  • 788 Views
  • 13 CrossRef citations
  • 0Altmetric

Systematic review

Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review
Anthony Yu, Eva Huang, Momoka Abe, Kang An, Sun-Kyeong Park & Chanhyun Park
Pages: 381-393
Published online: 22 Feb 2021
AbstractforCost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review | Full Text | References | PDF (881.1 KB) | EPUB
  • 545 Views
  • 5 CrossRef citations
  • 0Altmetric

Original research

Article
Association of congestive heart failure with hospital outcomes among renal cancer patients in the United States: analysis of nationwide inpatient sample
Sun-Kyeong Park, Lindsay Park, Ciara Silverman, Ji-Haeng Heo & Chanhyun Park
Pages: 395-402
Published online: 15 Mar 2021
AbstractforAssociation of congestive heart failure with hospital outcomes among renal cancer patients in the United States: analysis of nationwide inpatient sample | Full Text | References | PDF (298.3 KB) | EPUB | Supplemental
  • 99 Views
  • 2 CrossRef citations
  • 0Altmetric
Article
Micro-costing diagnostics in oncology: from single-gene testing to whole- genome sequencing
Clémence T. B. Pasmans, Bastiaan B. J. Tops, Elisabeth M. P. Steeghs, Veerle M. H. Coupé, Katrien Grünberg, Eiko K de Jong, Ed M. D. Schuuring, Stefan M. Willems, Marjolijn J. l. Ligtenberg, Valesca P. Retèl, Hans van Snellenberg, Ewart de Bruijn, Edwin Cuppen & Geert W. J. Frederix
Pages: 413-414
Published online: 06 May 2021
AbstractforMicro-costing diagnostics in oncology: from single-gene testing to whole- genome sequencing | Full Text | References | PDF (4.9 MB) | EPUB
  • 3818 Views
  • 8 CrossRef citations
  • 0Altmetric
Open Access
Article
Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia
Terence Khoo & Lan Gao
Pages: 415-423
Published online: 06 Dec 2020
AbstractforCost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia | Full Text | References | PDF (1.9 MB) | EPUB | Supplemental
  • 453 Views
  • 5 CrossRef citations
  • 0Altmetric

Original Research

Article
Analysis of hospital incidence and direct medical costs of intrahepatic cholangiocarcinoma in Spain (2000-2018)
Josep Darbà & Alicia Marsà
Pages: 425-431
Published online: 08 Nov 2020
AbstractforAnalysis of hospital incidence and direct medical costs of intrahepatic cholangiocarcinoma in Spain (2000-2018) | Full Text | References | PDF (2.4 MB) | EPUB
  • 149 Views
  • 1 CrossRef citations
  • 0Altmetric

Original research

Article
Patient associations and clinical oncology research: how much does a patient’s voice really matter?
Veronica Franchina, Celeste Cagnazzo, Alessandro Di Costanzo, Francesca Arizio, Angela Maria Elena Frazzetto, Stefania Gori, Rosita Cenna, Fabrizio Nicolis, Giuseppe Procopio, Vincenzo Adamo, Nicla La Verde & Oriana Nanni
Pages: 433-440
Published online: 26 Nov 2020
AbstractforPatient associations and clinical oncology research: how much does a patient’s voice really matter? | Full Text | References | PDF (649 KB) | EPUB
  • 119 Views
  • 3 CrossRef citations
  • 0Altmetric
Article
Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer
Li-Jen Cheng, Grace Wong, Wen-Yee Chay, Joanne Ngeow, Yongqiang Tan, Swee Sung Soon, Mohamed Ismail Abdul Aziz, Fiona Pearce & Kwong Ng
Pages: 441-448
Published online: 08 Mar 2021
AbstractforCost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer | Full Text | References | PDF (1.7 MB) | EPUB | Supplemental
  • 442 Views
  • 5 CrossRef citations
  • 0Altmetric

Original Research

Article
Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore
Li-Jen Cheng, Lydia Loke, Elaine Hsuen Lim, Fiona Pearce, Mohamed Ismail Abdul Aziz & Kwong Ng
Pages: 449-456
Published online: 17 Feb 2021
AbstractforCost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore | Full Text | References | PDF (1.5 MB) | EPUB
  • 438 Views
  • 7 CrossRef citations
  • 0Altmetric

Original research

Article
The impact of pharmaceutical innovation on the longevity and hospitalization of New Zealand cancer patients, 1998–2017
Frank R. Lichtenberg
Pages: 476-477
Published online: 15 Mar 2021
AbstractforThe impact of pharmaceutical innovation on the longevity and hospitalization of New Zealand cancer patients, 1998–2017 | Full Text | References | PDF (747.4 KB) | EPUB
  • 1519 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access
Article
Trends in the pricing and reimbursement of new anticancer drugs in South Korea: an analysis of listed anticancer drugs during the past three years
Sungju Kim, Jinhong Kim, Hyunyoung Cho, Kyungmin Lee, Chiyoung Ryu & Jong Hyuk Lee
Pages: 479-488
Published online: 17 Dec 2020
AbstractforTrends in the pricing and reimbursement of new anticancer drugs in South Korea: an analysis of listed anticancer drugs during the past three years | Full Text | References | PDF (618.5 KB) | EPUB
  • 386 Views
  • 7 CrossRef citations
  • 0Altmetric

Original Research

Article
Cost-utility analysis of stereotactic body radiotherapy plus cetuximab in previously irradiated recurrent squamous cell carcinoma of the head and neck
Henry WC Leung, Hui-Chu Lang, Shyh-Yau Wang, John Hang Leung & Agnes LF Chan
Pages: 489-495
Published online: 17 Mar 2021
AbstractforCost-utility analysis of stereotactic body radiotherapy plus cetuximab in previously irradiated recurrent squamous cell carcinoma of the head and neck | Full Text | References | PDF (1.4 MB) | EPUB
  • 107 Views
  • 2 CrossRef citations
  • 0Altmetric

Original research

Article
The challenge of value-based pricing in combination therapy: the case of trastuzumab and pertuzumab in HER2+ metastatic breast cancer
Boshen Jiao & Louis P. Garrison , Jr.
Pages: 497-504
Published online: 08 Apr 2021
AbstractforThe challenge of value-based pricing in combination therapy: the case of trastuzumab and pertuzumab in HER2+ metastatic breast cancer | Full Text | References | PDF (582.9 KB) | EPUB
  • 298 Views
  • 2 CrossRef citations
  • 0Altmetric

Original Research

Article
The challenge of sustainability in healthcare systems: economic and organizational impact of subcutaneous formulations for rituximab and trastuzumab in onco-hematology
Mattia Altini, Nicola Gentili, William Balzi, Gerado Musuraca, Roberta Maltoni, Carla Masini, Francesca Galardi, Lucia Bertoni & Ilaria Massa
Pages: 503-509
Published online: 13 May 2020
AbstractforThe challenge of sustainability in healthcare systems: economic and organizational impact of subcutaneous formulations for rituximab and trastuzumab in onco-hematology | Full Text | References | PDF (917.1 KB) | EPUB
  • 257 Views
  • 4 CrossRef citations
  • 0Altmetric

Original research

Article
Budget impact analysis of subcutaneous trastuzumab compared to intravenous trastuzumab in Saudi HER2-positive breast cancer patients
Shereef Elsamany, Gihan Hamdy Elsisi, Fayza Hassanin & Mohamed Jafal
Pages: 511-518
Published online: 22 Dec 2020
AbstractforBudget impact analysis of subcutaneous trastuzumab compared to intravenous trastuzumab in Saudi HER2-positive breast cancer patients | Full Text | References | PDF (956.5 KB) | EPUB
  • 193 Views
  • 3 CrossRef citations
  • 0Altmetric

Explore articles